Evidence map›Paper›PMID 40760270›Full record

ReviewMedical oncology (Northwood, London, England)2025

The role of HOXA1 in cancer and targeted therapy.

Jianshu Dong, Huimin Gong, Jian Li, Xinli Ma, Bilal Tayyab, Xia Xu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jianshu DongSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China. jdong@zzu.edu.cn.
Huimin GongSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Jian LiChina-US(Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China.
Xinli MaChina-US(Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China.
Bilal TayyabSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Xia XuSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China. xuxia@zzu.edu.cn.

Funding

National Natural Science Foundation of China 31900913
6 · The paper itself

Abstract

HOXA1 is a member of the HOX gene family, encoding a DNA-binding transcription factor that regulates gene expression, morphogenesis, cell proliferation, and differentiation. It plays a crucial role in the normal development of the human head, nervous system, heart, and brain vascular system. Numerous studies have shown that dysregulation of HOXA1 is associated with developmental abnormalities, various human diseases, and cancer. In this review, we summarize the role of the HOXA1 gene in different cancers. Additionally, we delve into the regulatory mechanisms of HOXA1 in carcinogenesis and tumor progression, upstream and downstream target genes, and pathway regulation. Finally, we emphasize its potential as a target for cancer diagnosis and treatment, proposing strategies for targeting HOXA1, related non-coding proteins, and the HOXA1/PBX dimer in cancer therapy.

Indexed as

Homeodomain ProteinsMolecular Targeted TherapyNeoplasmsTranscription FactorsAnimalsGene Expression Regulation, NeoplasticHomeobox A1 ProteinHumansHomeobox A1 ProteinHomeodomain ProteinsTranscription FactorsCancerHOXA1HOX geneTargeted therapyTranscriptional factor

Identifiers

PMID40760270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.